January 01, 2006

New Med: Bifeprunox Delayed

H. Lundbeck A/S announced that the ongoing review of bifeprunox clinical data has led to a delayed submission of a registration dossier in the European Union, now aimed for 2008, depending on the completion of additional phase III comparative clinical work.

Bifeprunox is a novel compound (a D2 and 5-HT1A partial agonist) for the treatment of schizophrenia and other mood disorders, such as bipolar disorder.

Source: Lundbeck A/S


Post a comment

Please enter this code to enable your comment -
Remember Me?
(you may use HTML tags for style)
* indicates required